



## ACL Tears At a Glance<sup>1</sup>

- ✓ ~200K anterior cruciate ligament (ACL) tears occur each year in the US.<sup>2</sup>
- ✓ People with ACL tears are at **increased risk for developing knee osteoarthritis**.
- ✓ Up to **75% of ACL tears are treated via surgical reconstruction**, which often uses tendon grafts from other body parts.<sup>3-5</sup>
- ✓ Potential ACL reconstruction risks<sup>6</sup> :
  - Graft site **pain**
  - **Decreased mobility**
  - **Graft tearing** over time, which may require revision surgery

Given these potential risks, the Regenexx approach aims to **preserve the ACL rather than replace it.**<sup>a</sup>

Regenexx SD injectates provide a **non-surgical option** using injections of the patient's own stem cells from bone marrow concentrate (BMC).

<sup>a</sup>Procedures using Regenexx injectates address non-retracted full and partial ACL tears. The THINC report performed a cost-effectiveness analysis of the Regenexx approach vs. ACL reconstruction surgery for patients with non-retracted partial ACL tears only to provide a conservative estimate of surgery costs.

<sup>b</sup>QALY = Cost-effectiveness analysis metric rating how well different types of medical treatments extend and/or improve patients' lives.

<sup>c</sup>Simulated with a decision-analytical model.

<sup>d</sup>Total costs of Regenexx approach = direct costs of procedure using Regenexx injectates, braces, primary care physician, specialist visits, and post-procedure physical therapy.

<sup>e</sup>Total costs of ACL reconstructive surgery = direct costs of procedure, rehabilitation, and both surgical and nonsurgical treatment in cases where reinjury occurred.

### References

1. Boeren S, Abraham K, Frederix GWJ, van Lieshout C, van der Meulen MP. Regenexx: The Next Generation of Orthopedic Recovery for Anterior Cruciate Ligament Tears as an Alternative to Surgery. Utrecht, NL: THINC Healthcare; 2023.
2. Peterson JR, Krabak BJ. Anterior cruciate ligament injury: mechanisms of injury and strategies for injury prevention. Physical Medicine and Rehabilitation Clinics of North America. 2014;25(4):813-828.
3. Sanders TL, Maradit Kremers H, Bryan AJ, Larson DR, Dahm DL, Levy BA, et al. Incidence of anterior cruciate ligament tears and reconstruction: a 21-year population-based study. Am J Sports Med. 2016;44(6):1502-1507.
4. Leys T, Salmon L, Waller A, Linklater J, Pinczewski L. Clinical results and risk factors for reinjury 15 years after anterior cruciate ligament reconstruction: a prospective study of hamstring and patellar tendon grafts. Am J Sports Med. 2012;40(3):595-605.
5. Thompson SM, Salmon LJ, Waller A, Linklater J, Roe JP, Pinczewski LA. Twenty-year outcome of a longitudinal prospective evaluation of isolated endoscopic anterior cruciate ligament reconstruction with patellar tendon or hamstring autograft. Am J Sports Med. 2016;44(12):3083-3094.
6. Abram SGF, Judge A, Beard DJ, Price AJ. Rates of adverse outcomes and revision surgery after anterior cruciate ligament reconstruction: a study of 104,255 procedures using the National Hospital Episode Statistics Database for England, UK. Am J Sports Med. 2019;47(11):2533-2542.

© Regenexx Corporate 2025. All rights reserved. 01/25.

## THINC Cost-Effectiveness Report: The Regenexx Approach vs. Reconstruction Surgery for ACL Tears

**THINC.  
HEALTHCARE**

A healthcare innovation research institute that conducted the **first health technology assessment of its kind** evaluating cost-effectiveness and quality of life (QoL)<sup>b</sup>

### THINC Report Features



#### Compared cost-effectiveness

of injections that utilized BMC, which contains stem cells, with ACL reconstruction surgery and subsequent physical therapy in working-age adults (average age 37 years)<sup>c</sup>



#### Calculated cost and QoL outcomes

for Regenexx approach and ACL reconstruction surgery<sup>b,d,e</sup>



#### Analyzed data

from Regenexx approach clinical trials as well as ACL reconstruction surgery cost-effectiveness analyses and clinical trials

### THINC Report Key Findings

The THINC report found that compared with ACL reconstructive surgery, procedures using Regenexx injectates demonstrated:

**>\$4,000**  
cost savings  
at 2 years

**Improved**  
QoL

**~19% lower**  
total healthcare  
costs

### THINC Report Conclusion:

The Corporate Program's Regenexx protocols offer a significantly cost-effective option with improved QoL for ACL tear treatment.

**Learn More**

The THINC report calculated direct costs only in its analysis.